Navigation Links
Vion Reports 2007 Fourth Quarter and Year-End Results
Date:3/17/2008

development 5,519 4,987 24,198 21,484

Marketing, general and

administrative 2,042 1,527 8,429 5,787

Total operating expenses 7,561 6,514 32,627 27,271

Loss from operations (7,511) (6,508) (32,561) (27,249)

Interest income 787 434 3,390 1,994

Interest expense (1,483) -- (5,135) --

Other expense, net (26) (19) (30) (50)

Loss before income taxes (8,233) (6,093) (34,336) (25,305)

Income tax provision (benefit) (74) 8 (343) 42

Net loss ($8,159) ($6,101) ($33,993)($25,347)

Basic and diluted loss per share(1) ($1.18) ($0.92) ($5.05) ($3.83)

Weighted-average number of shares

of common stock outstanding(1) 6,898 6,628 6,737 6,620

(1) Adjusted for all periods presented to reflect the Company's

one-for-ten reverse stock split effected February 20, 2008.

CONDENSED CONSOLIDATED BALANCE SHEET DATA

December 31,

(In thousands) 2007 2006

Cash and cash equivalents $61,067 $30,914

Total assets 63,195 31,856

Convertible senior notes 54,275 --

Total liabilities 61,988 6,402

Shareholders' equity 1,207 25,454


'/>"/>
SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. AutoImmune Inc. Reports 2007 Fourth Quarter and Year End Financial Results
2. Renovis Reports Fourth Quarter and Full Year 2007 Financial Results
3. Warner Chilcott Reports the Death of Its Director James Andress
4. Nile Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results
5. Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
6. Unigene Restates Policy on Analyst Reports
7. NPS Pharmaceuticals Reports 2007 Financial Results
8. Trubion Pharmaceuticals Inc. Reports Fourth-Quarter and Year-Ended 2007 Financial Results and Provides 2008 Financial Outlook
9. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
10. Dendreon Reports Fourth Quarter and 2007 Year End Financial Results
11. MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... April 16, 2015 OncoTAb, ... Charlotte (UNC Charlotte) spin-out company, announced today the ... Ph.D., M.D., as Chief Operating Officer (COO). Cooper ... experience in developing clinical diagnostic and biotechnology platforms ... disease. , Cooper’s extensive career transcends the field ...
(Date:4/16/2015)... - Bioenterprise Corporation is pleased to announce that it will ... , PEI.  Bioenterprise has established a 3-year strategic ... the commercialization of agricultural technologies and innovations. ... They have been at the heart of agri-innovation in ... Dave Smardon , President & CEO of Bioenterprise Corporation.  ...
(Date:4/16/2015)... SAN DIEGO , April 16, 2015 ... company dedicated to improving cancer surgeries, announced today that ... lead fluorescent cancer illuminator, AVB-620, in women with primary, ... trial, the company also welcomed the addition of ... affairs. The open label, dose escalation study ...
(Date:4/16/2015)... BETHESDA, Md. , April 16, 2015 /PRNewswire/ ... Bio"), a biotechnology company developing non-toxic DCVax® personalized ... has been included in the Loncar Cancer Immunotherapy ... help investors better track the immunotherapy field within ... founders have selected "the top 25 companies" in ...
Breaking Biology Technology:OncoTAb Names Dr. David L. Cooper as COO 2Bioenterprise Corporation Expands into the Maritimes 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 3NW Bio Included In New Index Of The "Top 25 Cancer Immunotherapy Companies" 2NW Bio Included In New Index Of The "Top 25 Cancer Immunotherapy Companies" 3
... 5 Experts from PAREXEL International Corporation (Nasdaq: ... services provider, will address important industry issues at ... being held from March 23 - 25, 2009 ... leaders will present on topics ranging from global ...
... BEACH, California and AMSTERDAM, March 5 ,Agendia, a ... the,appointment of Dr. Albert A. (Al) Luderer to ... Dr. Luderer has more than 30 years of ... therapeutic development. Currently, he,is the Chief Executive Officer ...
... WALTHAM, Mass., March 5 Proteon Therapeutics, Inc., announced ... Series B equity financing, led by MPM Capital on ... L.P. This announcement follows the initiation of a ... PRT-201, in patients with end stage renal disease undergoing ...
Cached Biology Technology:PAREXEL Experts to Present Leading Insights at Drug Information Association 21st Annual Euromeeting 2PAREXEL Experts to Present Leading Insights at Drug Information Association 21st Annual Euromeeting 3PAREXEL Experts to Present Leading Insights at Drug Information Association 21st Annual Euromeeting 4PAREXEL Experts to Present Leading Insights at Drug Information Association 21st Annual Euromeeting 5Agendia Appoints Seasoned Diagnostics Executive Albert A. Luderer to Supervisory Board 2Proteon Therapeutics Completes $38M Equity Financing; Initiates Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients and Signs Option Agreement With Major Pharmaceutical Company 2
(Date:3/30/2015)... DUBLIN , Mar. 26, 2015 Research and ... addition of the "Global Gesture Recognition Market in ... The analysts forecast the Global Gesture Recognition market ... 12.8% over the period 2013-2018. Gesture recognition ... respond to different gestures of an individual. Gesture recognition ...
(Date:3/24/2015)... March 24, 2015   Crossmatch ™, a ... announced that its U.are.U ® 4500 Fingerprint ... Goorin Bros . to achieve PCI compliance for ... access to the POS terminal, protecting the retailer ... data breaches. With one-third of ...
(Date:3/20/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/4stcg3/india_sensors ) ... Sensors Market Forecast and Opportunities 2020" report ... is projected to grow at a CAGR over ... industrial and healthcare sectors are the key application ... adoption of MEMS technology in sensors is growing ...
Breaking Biology News(10 mins):Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3
... Lugano, Switzerland, 14 September 2012 -- Ahead of the ... be released during the ESMO 2012 Congress, over 1,600 ... 2012 at 9:00 (CEST) to anticipate the flavor of ... emerging strategies set to combat cancer, signposting future directions ...
... have developed a method that for the first time ... proteins and subsequently remove them in a repeatable cycle., ... this week in the journal Nature Methods , ... naturally formed proteins in order to create better antibiotics, ...
... ,Boston (Sept. 14, 2012) Eye injuries in ... as weapons, tactics, technology and strategies have evolved. ... cause extensive damage areas not protected by body armor. ... Institute, Massachusetts Eye and Ear will convene in Boston, ...
Cached Biology News:Noteworthy studies at the ESMO 2012 Congress 2Noteworthy studies at the ESMO 2012 Congress 3Noteworthy studies at the ESMO 2012 Congress 4Noteworthy studies at the ESMO 2012 Congress 5Noteworthy studies at the ESMO 2012 Congress 6Noteworthy studies at the ESMO 2012 Congress 7Chemists develop reversible method of tagging proteins 2Chemists develop reversible method of tagging proteins 3
... depletion cocktail is tailored to ... from suspensions of non-human primate ... separated using the StemSep (or ... selection system, achieving a 2.6 ...
... is tailored to highly enrich ... of non-human primate (Rhesus monkey) ... the StemSep compatible 0.5 Tesla) ... CD4+ T cell content of ...
Mol wt: monoisotopic mol wt1,045.5423 Da by calculation...
...
Biology Products: